CClinicalTrials.gg
Status unknownNCT03855943Updated Apr 1, 2022

Evaluating the Effects of a Computerized Training Program Coupled With Cognitive Behavioral Therapy (CBT) for OCD.

An interventional study of Personalized Computer Program and CBT in Obsessive-Compulsive Disorder, sponsored by Hebrew University of Jerusalem. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-01.

Sponsored by Hebrew University of Jerusalem · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the effects of a computerized training program coupled with cognitive behavioral therapy (CBT) for OCD.

Read the detailed description

This study will evaluate the effectiveness of a computerized training program (called Personalized Computerized Inhibitory Training, or PCIT) coupled with cognitive behavioral therapies (CBT) consisting of Exposures and Response Prevention in treating obsessive compulsive disorder (OCD) in patients who previously underwent CBT, but still have residual symptoms.

02

Conditions studied

  • Obsessive-Compulsive Disorder
03

In context

Obsessive-Compulsive Disorder

606 studies on the registry are indexed under Obsessive-Compulsive Disorder; 160 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 492 interventional studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Hebrew University of Jerusalem is the lead sponsor of 31 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Principal diagnosis of OCD (assessed by SCID).
  • Clinically significant OCD symptoms (Y-BOCS score of at least 14).
  • Allowed to be on medications if they have been on a stable dose for at least 12 weeks prior to the study and will remain on a stable dose during this study.
  • Have access to a computer or laptop.

Exclusion criteria

Exclusion Criteria:

  • Individuals with the following disorders will excluded: bipolar, psychosis, current major depressive disorder (assessed by SCID).
  • Patients with head injury and loss of consciousness of more than five minutes or a neurological condition affecting the central nervous system.
  • Patients taking a psychiatric medication will be asked to maintain a stable dose for 6 weeks prior to study entry.
  • Patients with a history of more than 8 hours of therapist-assisted ERP for OCD in the past 6 months,
  • Vision or hearing loss (although individuals with vision corrected by glasses or contacts will not be excluded).
  • Active suicidality warranting immediate clinical care.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CBT + Personalized Computer Program

    Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program

    Behavioral: Personalized Computer Program · Behavioral: CBT

Interventions

  • BehavioralPersonalized Computer Program

    Training with a personalized computerized inhibitory training program

  • BehavioralCBT

    Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy

06

What researchers measure

Primary outcomes

  1. Obsessive-compulsive symptoms measured after 3 weeks of treatment

    Measured by Yale-Brown Obsessive Compulsive Scale (YBOCS), considered the gold standard assessment tool. Y-BOCS comprises a Symptom Checklist and Severity Scale to consecutively rate obsessions and compulsions. The Checklist includes 54 common obsessions and compulsive behaviors, which are grouped according to thematic content. Symptoms that are endorsed over the past week are then globally rated by the clinician using a five-point scale ranging from 0 (none) to 4 (extreme) across five dimensions: (1) time/frequency, (2) interference, (3) distress, (4) resistance, and (5) degree of control. Obsessive and compulsive symptom severity are rated separately (scores range from 0 to 25) with these scores summed to create a total OCD severity score (range, 0-50). Symptom severity scores: mild symptoms (0-13), moderate symptoms (14-25), moderate-severe symptoms (26-34), and severe symptoms (35-40).26

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
  • Hebrew University of Jerusalem
    Jerusalem, 9190501, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03855943
Lead sponsor
Hebrew University of Jerusalem
Responsible party
Noa Tauber (Research Assistant, Hebrew University of Jerusalem) — Principal investigator
First posted
Feb 27, 2019
Start date
Apr 11, 2019
Primary completion
Mar 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Apr 1, 2022

Study contacts

Noa Tauber, MA
Contact
noa.tauber@mail.huji.ac.il
559714264 ext. 00972
Noa Tauber, MA
principal investigator · Hebrew University of Jerusalem

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion